Article
Comparison of three therapeutic regimens for genotype-3 hepatitis C virus infection in a large real-life multicentre cohort.
Liver international : official journal of the International Association for the Study of the Liver - 1 Apr 2020
Soria Alessandro, Fava Marco, Bernasconi Davide P, Lapadula Giuseppe, Colella Elisa, Valsecchi Maria G, Migliorino Guglielmo M, D'Ambrosio Roberta, Landonio Simona, Schiavini Monica, Spinetti Angiola, Carriero Canio, Degasperi Elisabetta, Cologni Giuliana, Gatti Federico, Viganò Paolo, Hasson Hamid, Uberti-Foppa Caterina, Pasulo Luisa, Baiguera Chiara, Rossotti Roberto, Vinci Maria, Puoti Massimo, Giorgini Alessia, Menzaghi Barbara, Lombardi Andrea, Pan Angelo, Aghemo Alessio, Grossi Paolo A, Boldizzoni Roberto, Colombo Silvia, Viganò Mauro, Rumi Maria G, Del Poggio Paolo, Valenti Luca, Giglio Omar, De Bona Anna, d'Arminio Monforte Antonella, Colombo Alberto, Spinelli Ombretta, Pigozzi Marie G, Molteni Chiara, Bonfanti Paolo, Terreni Natalia, Perini Paolo, Capretti Andrea, Bella Daniele, Liani Cecilia, Polo Silvia, Aimo Gianpiero, Pagnucco Layla, Bhoori Sherrie, Centenaro Riccardo, Graffeo Massimo, Ciaccio Antonio, Dionigi Elena, Lazzaroni Sergio, Carderi Isabella, Di Marco Mariella, Rizzardini Giuliano, Noventa Franco, Lampertico Pietro, Fagiuoli Stefano
Abstract excerpt
BACKGROUND & AIMS: In the direct-acting antiviral era, treatment of genotype-3 HCV (HCV-GT3) is still challenging. Real-life comparisons between recommended regimens, sofosbuvir (SOF)+daclatasvir (DAC), SOF/velpatasvir (VEL), glecaprevir/pibrentasvir (GLE/PIB), are scarce. We aimed at filling this data gap. METHODS: Sustained virological response 12 weeks after treatment completion (SVR12) was assessed for all...
Read the complete abstract on PubMed